Age-Dependent Decline in the Apolipoprotein E Level in Cerebrospinal Fluid from Control Subjects and Its Increase in Cerebrospinal Fluid from Patients with Alzheimer’s Disease

No abstract is available for this paper.

• Publication year

  2000

• Venue

  European Neurology

• Publication date

  2000-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000008157PMID 10765057
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease

  2006cited by this paper
• Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease

  2004cited by this paper
• Neurodegeneration: Chaperoning brain diseases

  1998cited by this paper
• A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia

  1998cited by this paper
• The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid

  1998cited by this paper
• The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-beta (A beta) 40, A beta 4242, apolipoprotein E and transthyretin in human cerebrospinal fluid.

  1998cited by this paper
• The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease.

  1998cited by this paper
• Increased Levels of Apolipoprotein D in Cerebrospinal Fluid and Hippocampus of Alzheimer's Patients

  1998cited by this paper
• Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition

  1997cited by this paper
• Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.

  1997cited by this paper
• Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease.

  1997cited by this paper
• Levels of cerebrospinal fluid apolipoprotein E in patients with Alzheimer's disease and healthy controls.

  1997cited by this paper
• Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease.

  1997cited by this paper
• Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein.

  1997cited by this paper
• Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins.

  1996cited by this paper
• Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study.

  1996cited by this paper
• Apolipoprotein E. Structure, Function, and Possible Roles in Alzheimer's Disease a

  1996cited by this paper
• Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease.

  1996cited by this paper
• Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?

  1996cited by this paper
• Cultured Leptomeningeal Cells Secrete Cerebrospinal Fluid Proteins

  1996cited by this paper
• Apolipoprotein E in cerebrospinal fluid from patients with Alzheimer's disease and other forms of dementia is reduced but without any correlation to the apoE4 isoform.

  1996cited by this paper
• Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid.

  1995cited by this paper
• Apolipoprotein E: a review of its roles in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Alzheimer's disease

  1995cited by this paper
• Development and application of a modified monoclonal hybridoma technique for isolating monoclonal antibodies to human brain regions.

  1995cited by this paper
• Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease.

  1995cited by this paper
• Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

  1994cited by this paper
• Expression of Apolipoprotein A‐I in Porcine Brain Endothelium In Vitro

  1994cited by this paper
• Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease

  1994cited by this paper
• Membrane Lipids, Selectively Diminished in Alzheimer Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination in Late‐Onset Form (Type II)

  1994cited by this paper
• Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

  1993cited by this paper
• Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.

  1993cited by this paper
• Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid.

  1992cited by this paper
• Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker.

  1992cited by this paper
• Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid.

  1991cited by this paper
• Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning.

  1991cited by this paper
• Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes

  1991cited by this paper
• Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

  1990cited by this paper
• Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.

  1988cited by this paper
• Comparison of four procedures for separating apolipoprotein A- and apolipoprotein B-containing lipoproteins in plasma.

  1987cited by this paper
• Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.

  1987cited by this paper
• Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome

  1986cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• "Ultrasensitive" silver stains: their use exemplified in the study of normal human cerebrospinal fluid proteins separated by two-dimensional electrophoresis.

  1984cited by this paper
• Apolipoproteins in human cerebrospinal fluid.

  1979cited by this paper

• Cerebrospinal fluid lipoprotein-mediated cholesterol delivery to neurons is impaired in Alzheimer's disease and involves APOE4

  2025cites this paper
• Impaired Cerebrospinal Fluid Lipoprotein-Mediated Cholesterol Delivery to Neurons in Alzheimer’s Disease

  2024cites this paper
• Serum Levels of α-Klotho Are Correlated with Cerebrospinal Fluid Levels and Predict Measures of Cognitive Function

  2022cites this paper
• Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis

  2019cites this paper
• Perturbed Brain Energy Metabolism in Alzheimer’s Disease and Diabetes

  2017cites this paper
• Reconstituted high-density lipoproteins acutely reduce soluble brain Aβ levels in symptomatic APP/PS1 mice.

  2016cites this paper
• Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma*

  2016cites this paper
• Meta-analysis of apolipoprotein E levels in the cerebrospinal fluid of patients with Alzheimer's disease.

  2016cites this paper
• Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease

  2015cites this paper
• Meta-Review of CSF Core Biomarkers in Alzheimer’s Disease: The State-of-the-Art after the New Revised Diagnostic Criteria

  2014cites this paper
• High-density lipoproteins and cerebrovascular integrity in Alzheimer's disease.

  2014influential citation
• Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease

  2014influential citation
• CSF Apo-E levels associate with cognitive decline and MRI changes

  2014cites this paper
• Total ApoE and ApoE4 Isoform Assays in an Alzheimer's Disease Case-control Study by Targeted Mass Spectrometry (n = 669): A Pilot Assay for Methionine-containing Proteotypic Peptides*

  2012cites this paper
• Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women

  2012cites this paper
• APOE ε4 allele and CSF APOE on Cognition in HIV-Infected Subjects

  2011influential citation
• 24s-Hydroxycholesterol. Studies on regulatory mechanisms behind its formation in the brain and its potential use as a marker for neurodegeneration

  2010cites this paper
• Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients

  2009cites this paper
• Cholesterol and late-life cognition. An epidemiological and clinical approach

  2009cites this paper
• Changes in protein levels as markers of severe disease: an investigation of severe malaria

  2008cites this paper
• The distribution of apolipoprotein E in mouse olfactory epithelium.

  2007cites this paper
• Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders.

  2007cites this paper
• Role of IKK and oscillatory NFκB kinetics in MMP‐9 gene expression and chemoresistance to 5‐fluorouracil in RKO colorectal cancer cells

  2007cites this paper
• A better understanding of molecular mechanisms underlying human disease

  2007cites this paper
• Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration

  2007cites this paper
• Proteomics‐driven progress in neurodegeneration research

  2006cites this paper
• Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects

  2006cites this paper
• Is there a relation between APOE expression and brain amyloid load in Alzheimer’s disease?

  2005cites this paper
• Proteomics analysis of human cerebrospinal fluid.

  2005cites this paper
• The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease.

  2003cites this paper
• APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.

  2002cites this paper
• Proteomics in experimental gerontology.

  2002cites this paper
• APOE-ε4 and APOE −491A polymorphisms in individuals with subjective memory loss

  2002cites this paper
• Alzheimer's disease biomarkers: their value in diagnosis and clinical trials.

  2002cites this paper
• An investigation into risk factors of Alzheimer's disease : association with pre-clinical, clinical and autopsy confirmed AD

  2002cites this paper
• Bibliography of Multi-Lingual Mini Mental State Examination

  2001cites this paper
• The Cerebrospinal Fluid Level of Glial Fibrillary Acidic Protein Is Increased in Cerebrospinal Fluid from Alzheimer’s Disease Patients and Correlates with Severity of Dementia

  2001cites this paper
• Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity.

  2001cites this paper
• Current awareness

  2000cites this paper